首页> 外文OA文献 >Targeted Therapies: Adaptive Sequential Designs For Subgroup Selection In Clinical Trials
【2h】

Targeted Therapies: Adaptive Sequential Designs For Subgroup Selection In Clinical Trials

机译:靶向治疗:临床试验中亚组选择的适应性顺序设计

摘要

A critical part of clinical trials in drug development is the analysis of treatment efficacy in patient subgroups (subpopulations). Due to multiplicity and the small sample sizes involved, this analysis presents substantial statistical challenges and can lead to misleading conclusions. In this thesis, we develop methodology for statistically valid subgroup analysis in a variety of settings. First, we consider a number of trial designs of varying flexibility for the case of one subgroup of interest. Some procedures are novel, while others are adapted from the literature. Included is data-driven consideration of adaptive change of subject eligibility criteria-known as adaptive enrichment-whereby apparently nonresponsive patient populations are not recruited after data has been unblinded for an interim analysis. We conduct an extensive numerical study to investigate design operating characteristics, as well as sensitivity to subgroup prevalence and interim analysis timing. We observe that power gains can be substantial when a treatment is only effective in the subgroup of interest. Following this example, selected procedures are generalized to allow for analysis of an arbitrary number of subgroups. Next, we propose a K -stage group sequential design that can be applied as a confirmatory seamless Phase II/III design. The design is specified through upper and lower spending functions, defined in terms of calendar times. After the first stage, poorly performing subgroups are eliminated and the remaining population is pooled for the duration of the trial. This procedure combines the elimination of non-sensitive subgroups with the definitive assessment of treatment efficacy associated with traditional group sequential designs. Numerical examples show that the procedure has high power to detect subgroup-specific effects, and the use of multiple interim analysis points can lead to substantial sample size savings. We address the challenges of adjusting for selection bias, and protecting the familywise error rate in the strong sense. All designs are presented either in terms of standardized test statistics or the efficient score, making the analysis of normal, binary, or time-to-event data straightforward.
机译:药物开发临床试验的关键部分是分析患者亚组(亚群)的治疗效果。由于多样性和涉及的样本量小,该分析提出了重大的统计挑战,并可能导致误导性结论。在本文中,我们开发了在各种环境中进行统计有效的亚组分析的方法。首先,我们考虑针对一个感兴趣的亚组情况的多种灵活性不同的试验设计。有些程序是新颖的,而另一些则是根据文献改编的。包括以数据为依据的对受试者资格标准的适应性变化的考虑,这被称为适应性充实,因此在对数据进行盲目的中期分析后,显然没有招募无反应的患者人群。我们进行了广泛的数值研究,以调查设计的工作特性以及对亚组患病率和中期分析时间的敏感性。我们观察到,当治疗仅在感兴趣的亚组中有效时,功率增益会很大。在此示例之后,概括了选定的过程以允许分析任意数量的子组。接下来,我们提出一个K级小组顺序设计,该设计可以用作验证性的无缝II / III期设计。通过日历时间定义的上限和下限支出功能指定设计。在第一阶段之后,将表现不佳的亚组排除在外,并在试验期间合并剩余的人群。该程序将消除非敏感亚组与确定与传统组序贯设计相关的治疗效果结合起来。数值示例表明,该程序具有检测特定于亚组的效果的强大功能,并且使用多个临时分析点可以节省大量样本。我们从严格的意义上解决调整选择偏见和保护家庭错误率的挑战。所有设计均以标准化测试统计数据或有效评分的形式呈现,从而使对常规,二进制或事件时间数据的分析变得简单明了。

著录项

  • 作者

    Magnusson Baldur;

  • 作者单位
  • 年度 2011
  • 总页数
  • 原文格式 PDF
  • 正文语种 en_US
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号